Literature DB >> 3056237

Comparison of antibiotic activities by using serum bactericidal activity over time.

B J Guglielmo1, L C Rodondi.   

Abstract

In evaluating antimicrobial agents with similar spectra of activity, it is difficult to determine equivalent dosage regimens. In vitro potency, pharmacokinetic disposition, and other factors determine the usual dosing regimen. Knowledge of the serum bactericidal activity over time may assist in defining the potency of comparative antimicrobial agents. Cefoxitin and ceftizoxime, cephalosporins with gram-negative aerobic and anaerobic activity, have been promoted as monotherapy in the treatment of intra-abdominal infection. In a randomized, crossover study, six healthy volunteers received single 30-mg/kg doses of cefoxitin and ceftizoxime. Greater serum activity against Escherichia coli and Bacteroides fragilis was observed with ceftizoxime than with cefoxitin. The results suggest that ceftizoxime can be administered in a lower daily dosage than cefoxitin. We propose that the present study may serve as a prototype for future studies attempting to assess equivalent dosing regimens for antibiotics with similar spectra of activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056237      PMCID: PMC175909          DOI: 10.1128/AAC.32.10.1511

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve.

Authors:  S L Barriere; E Ely; J E Kapusnik; J G Gambertoglio
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

2.  Clinical comparison of cefotaxime versus the combination of gentamicin plus clindamycin in the treatment of peritonitis and similar polymicrobial soft-tissue surgical sepsis.

Authors:  H H Stone; C E Geheber; L D Kolb; W E Dunlop
Journal:  Clin Ther       Date:  1981       Impact factor: 3.393

3.  In-vitro activity of ceftizoxime against anaerobic bacteria and comparison with other cephalosporins.

Authors:  A W Chow; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1982-11       Impact factor: 5.790

Review 4.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

Review 5.  Cefamandole and cefoxitin.

Authors:  C V Sanders; R N Greenberg; R L Marier
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

6.  A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections.

Authors:  G L Drusano; J W Warren; A J Saah; E S Caplan; J H Tenney; S Hansen; J Granados; H C Standiford; E H Miller
Journal:  Surg Gynecol Obstet       Date:  1982-05

7.  Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

  7 in total
  4 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.

Authors:  R G Deeter; M P Weinstein; K A Swanson; J S Gross; L C Bailey
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Serum bactericidal activity after administration of four cephalosporins in healthy volunteers.

Authors:  S Lemmen; A Kropec; I Engels; A Busse; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-11       Impact factor: 3.267

4.  Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.

Authors:  Gary E Stein; Sharon Schooley; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.